DPI-287

From WikiMD's Food, Medicine & Wellness Encyclopedia

DPI-287.svg

DPI-287 is a synthetic opioid analgesic drug that is a highly selective agonist for the delta opioid receptor. It was developed as part of ongoing research into the potential therapeutic benefits of delta opioid receptor agonists, which are believed to have analgesic properties without the addictive potential and respiratory depression associated with mu opioid receptor agonists.

Pharmacology[edit | edit source]

DPI-287 exhibits high selectivity and affinity for the delta opioid receptor, which is one of the three main types of opioid receptors, the others being the mu opioid receptor and the kappa opioid receptor. Activation of the delta opioid receptor has been shown to produce analgesia, antidepressant effects, and neuroprotection. Unlike mu opioid receptor agonists, delta opioid receptor agonists like DPI-287 are less likely to cause tolerance and dependence.

Potential Therapeutic Uses[edit | edit source]

Research into DPI-287 and other delta opioid receptor agonists is ongoing, with potential applications in the treatment of chronic pain, depression, and neurodegenerative diseases. The unique properties of delta opioid receptor agonists make them promising candidates for new pain relief medications that do not carry the same risk of addiction and other side effects as traditional opioid drugs.

Side Effects[edit | edit source]

While delta opioid receptor agonists are generally considered to have a more favorable side effect profile compared to mu opioid receptor agonists, they are not without risks. Potential side effects of DPI-287 may include nausea, dizziness, and headache. Further research is needed to fully understand the safety and efficacy of DPI-287 in clinical settings.

Research and Development[edit | edit source]

DPI-287 is still in the experimental stages of development, with preclinical studies showing promising results. Researchers are continuing to investigate its pharmacological properties, therapeutic potential, and safety profile. The development of DPI-287 and similar compounds could represent a significant advancement in the field of pain management and the treatment of other conditions.

See Also[edit | edit source]

References[edit | edit source]


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD